Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Structure Based Prediction of Neoantigen Immunogenicity.

Riley TP, Keller GLJ, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR, Baker BM.

Front Immunol. 2019 Aug 28;10:2047. doi: 10.3389/fimmu.2019.02047. eCollection 2019.

2.

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers.

Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA, Saharinen P, Salmenkivi K, Mäyränpää MI, Wennerberg K, Verschuren EW.

Mol Cancer Ther. 2019 Oct;18(10):1863-1874. doi: 10.1158/1535-7163.MCT-18-0573. Epub 2019 Jul 18.

PMID:
31320402
3.

Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Hellman LM, Foley KC, Singh NK, Alonso JA, Riley TP, Devlin JR, Ayres CM, Keller GLJ, Zhang Y, Vander Kooi CW, Nishimura MI, Baker BM.

Mol Ther. 2019 Feb 6;27(2):300-313. doi: 10.1016/j.ymthe.2018.12.010. Epub 2018 Dec 14.

PMID:
30617019
4.

More than a Tumor Suppressor: E-Cadherin Loss Drives Lung Cancer Metastasis.

Devlin JR, Verschuren EW.

Am J Respir Cell Mol Biol. 2018 Aug;59(2):141-142. doi: 10.1165/rcmb.2018-0063ED. No abstract available.

PMID:
29688752
5.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

6.

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.

Nagaraj AS, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin JR, Salmenkivi K, Kallioniemi O, Mäyränpää MI, Närhi K, Verschuren EW.

Cell Rep. 2017 Jan 17;18(3):673-684. doi: 10.1016/j.celrep.2016.12.059.

7.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L.

Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2.

8.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

9.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.

10.

Bifunctional Zn(II) complexes for recognition of non-canonical thymines in DNA bulges and G-quadruplexes.

Siters KE, Sander SA, Devlin JR, Morrow JR.

Dalton Trans. 2015 Feb 28;44(8):3708-16. doi: 10.1039/c4dt03004d.

PMID:
25521076
11.

Targeting the nucleolus for cancer intervention.

Quin JE, Devlin JR, Cameron D, Hannan KM, Pearson RB, Hannan RD.

Biochim Biophys Acta. 2014 Jun;1842(6):802-16. doi: 10.1016/j.bbadis.2013.12.009. Epub 2014 Jan 2. Review.

12.

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.

Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, Hall MN, Wall M, Hannan RD, Pearson RB, McArthur GA, Johnstone RW.

Blood. 2013 Apr 11;121(15):2964-74. doi: 10.1182/blood-2012-08-446096. Epub 2013 Feb 12.

13.

AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.

Devlin JR, Hannan KM, Ng PY, Bywater MJ, Shortt J, Cullinane C, McArthur GA, Johnstone RW, Hannan RD, Pearson RB.

FEBS J. 2013 Nov;280(21):5307-16. doi: 10.1111/febs.12135. Epub 2013 Feb 13.

Supplemental Content

Loading ...
Support Center